https://mots.peptidesphoenix.com/blogs/news 2026-08-11T00:03:17-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/aod-9604-in-the-glp-1-era-fda-s-evolving-peptide-stance 2026-07-21T08:01:26-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/mots-c-regulatory-status-fda-enforcement-and-research-implications 2026-07-23T00:02:15-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/mots-c-and-fda-s-peptide-panel-what-the-vote-means 2026-07-28T00:02:47-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/aod-9604-and-the-fda-peptide-panel-vote-compounding-access-and-off-label-research 2026-07-30T00:02:25-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/mots-c-and-the-fda-s-peptide-panel-how-the-vote-could-shape-regulatory-pathways-for-mitochondrial-peptides 2026-08-04T00:01:48-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/mots-c-and-the-fda-s-6-peptide-backing-navigating-the-regulatory-ripple-for-mitochondrial-peptides 2026-08-06T00:03:35-05:00 weekly https://mots.peptidesphoenix.com/blogs/news/mots-c-reddit 2026-08-11T00:03:17-05:00 weekly